200 300 400 500 600 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg Final results of the APEX study in MESI. Includes patients in the per protocol set that completed the Week 4 visit and met all the eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). One patient in the 10 mg dose level discontinued after Week 12 due to recurrent uveitis flare-up. Meaningful anatomical improvements are rapidly achieved, with OCT CST levels <325 μm observed in the top two dose levels as early as Week 1, further deepening over time Mean CST (μm) Observed OCT CST over time Reading Center Data Dose Level Dryness (CST 250-325) 2.5 mg 13 12 13 13 13 13 13 12 5 mg 13 13 13 13 13 13 13 13 10 mg 13 13 13 13 13 12 12 12 Sample Size Mean Change -214 -226 -116 Weeks 8 Rapid improvement demonstrated within 1 week 1